Dear Doctor - Participate in the Survey on serious skin infection "A new survey has found that serious skin infections are on the rise in the United States. The survey, conducted by the Centers for Disease Control and Prevention (CDC), found that the number of people hospitalized for skin infections rose by nearly 8 percent between 2011 and 2012.The most common type of infection was cellulitis, which accounted for more than 60 percent of all cases. Cellulitis is a bacterial infection that affects the deep layers of the skin. It can be painful and often requires hospitalization.Other types of serious skin infections include MRSA (methicillin-resistant Staphylococcus aureus), impetigo, and shingles. The CDC recommends that people take steps to prevent these infections, such as washing hands regularly and avoiding contact with contaminated surfaces. Participate now."
1.
enhancing survivors of brain tumors' quality of life.
2.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
3.
A protein with new anticancer activity has been identified
4.
Studies point to redlining as a 'perfect storm' for breast cancer
5.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care
3.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
4.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
5.
Progressive Strategies in Oncology and Patient Outcomes
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Managing Common Side Effects During Cancer Treatment
5.
Clinical Insights in Oncology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation